A recent study has shown that the adjunctive use of an antibacterial envelope significantly reduces incidence of major cardiac implantable electronic device (CIED) infections, without a higher incidence of complications, compared with standard-of-care infection-prevention strategies alone.
The use of glecaprevir plus pibrentasvir appears to be safe and highly effective in the treatment of chronic hepatitis C virus (HCV) infection genotypes 1–3 in patients with severe renal impairment, including those undergoing haemodialysis, as shown in a recent study from Japan.
A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.
Long-term results of the POET* trial have suggested that patients with left-sided infective endocarditis (IE) could safely switch from conventional intravenous (IV) antibiotics to oral antibiotics, with oral antibiotics associated with a reduced mortality risk.
In intravenous drug users, hospital admissions for infective endocarditis (IE) appear to be on the rise, with the prevailing treatment approach shifting away from surgical to medical, according to a new study presented at the recently concluded 68th Annual Scientific Session & Expo of the American College of Cardiology (ACC 2019).
The tetracycline omadacycline is not inferior to moxifloxacin when used as empirical monotherapy for hospitalized adults with community-acquired bacterial pneumonia, according to the results of a phase III study.
The aminoglycoside plazomicin has demonstrated noninferiority to meropenem, a broad-spectrum carbapenem antibiotic, for treating complicated urinary tract infection (UTI) and acute pyelonephritis, with the former yielding greater microbiologic eradication as reflected by lower incidences of recurrence and relapse, according to data from the phase III EPIC* trial.
Patients using long-acting opioids with immunosuppressive properties are at greater risk of developing serious infections compared with those using the nonimmunosuppressive opioid counterpart, according to a study.
A higher frequency of enterovirus, but not adenovirus, infection during early childhood may increase the risk of later coeliac disease, suggests a recent study, adding new data on the role of viral infections in the aetiology of coeliac disease.